secwatch.observer — SEC 8-K summary
======================================

Issuer:     Damora Therapeutics, Inc. (DMRA)
CIK:        0001800315
Form:       8-K
Filed at:   2023-08-15T23:59:59+00:00
Accession:  0000950170-23-042631
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galecto's Phase 2b GALACTIC-1 trial misses primary endpoint; GB0139 discontinued
--------------------------------------------------------------------------------

- GALACTIC-1 trial did not meet primary endpoint of FVC decline; change from baseline -316.6 mL vs -127.4 mL (placebo).
- Serious adverse events: 7.8% in GB0139 arm vs 1.4% placebo; worsening IPF observed.
- Cash and investments ~$49M as of July 31, 2023; evaluating resource allocation to extend runway into 2025.
- Shifting focus to liver diseases; GULLIVER-3 Phase 2a trial of GB1211 expected to start early 2024.
- No confirmation of target engagement; galectin-3 levels increased in both arms from day 0 to week 52.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800315/000095017023042631/0000950170-23-042631-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800315/000095017023042631/glto-20230815.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-042631

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer